Anti-MUC16 monoclonal antibody - Quest PharmaTech/AmrutBio

Drug Profile

Anti-MUC16 monoclonal antibody - Quest PharmaTech/AmrutBio

Alternative Names: Anti-MUC16 AR9.6; Anti-MUC16 mAb - Quest PharmaTech; AR 9.6; mAb-AR9.6

Latest Information Update: 30 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Nebraska Medical Center
  • Developer Quest PharmaTech
  • Class Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 30 Sep 2016 Pharmacodynamics data from preclinical trials in Cancer released by QuestPharmatech (Quest PharmaTech website, September 2016)
  • 16 Sep 2016 Preclinical trials in Cancer in USA (IV) prior to September 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top